Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 149-155

  Canini, Laetitia ^a,b,c   DebRoy, Swati ^b,d   Mariño, Zoe ^e   Conway, Jessica M ^a   Crespo, Gonzalo ^e   Navasa, Miquel ^e   D'Amato, Massimo ^f   Ferenci, Peter ^g   Cotler, Scott J ^b   Forns, Xavier ^e   Perelson, Alan S ^a   Dahari, Harel ^a,b  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SOUTH CAROLINA BEAUFORT   (United States)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f Rotta Research Laboratorium   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

SILIBININ; ANTIOXIDANT; SILYMARIN;

ADULT; AGE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CELL LOSS; CLINICAL ARTICLE; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; AGED; BIOAVAILABILITY; BLOOD; CELL DEATH; COMPLICATION; COMPUTER SIMULATION; DRUG EFFECTS; HEPACIVIRUS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CELL DEATH; COMPUTER SIMULATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEVERITY OF ILLNESS INDEX; SILYMARIN; VIRAL LOAD;

EID: 84937577851     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2806     Document Type: Article

References (31)

1. Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS ONE 2012; 7:e44103.
2. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference∗. J Viral Hepat 2011; 18 Suppl 1:1-16.
3. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687.
4. Dugum M, O'Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med 2014; 81:159-172.
5. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59:434-441.
6. Carrión JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-728.
7. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206-212.
8. Guedj H, Guedj J, Negro F, et al. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with PEG-IFN-alfa-2a and ribavirin. J Viral Hepat 2012; 19:488-496.
9. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135:1561-1567.
10. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56:1019-1024.
11. Mariño Z, Crespo G, D'Amato M, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2013; 58:415-420.
12. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
13. Shudo E, Ribeiro RM, Perelson AS. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 2009; 5:321-332.
14. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19:716-723.
15. Cuzick J. A Wilcoxon type test for trend. Stat Med 1985; 4:543-547.
16. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005; 42:491-498.
17. Wolf D. Evaluation of the size, shape, and consistency of the liver. Clinical methods: the history, physical, and laboratory examination. Boston: Butterworths 1990; p. 478-481.
18. Dahari H, Layden-Almer JE, Kallwitz E, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009; 136:1402-1409.
19. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLOS Comput Biol 2012; 8:e1002339.
20. Rong L, Guedj J, Dahari H, et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLOS Comput Biol 2013; 9:e1002959.
21. Mayer KE, Myers R, Lee S. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005; 12:559-567.
22. Guedj J, Neumann A. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010; 267:330-340.
23. Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009; 14:459-464.
24. Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007; 247:371-381.
25. DebRoy S, Mariño Z, Crespo G, et al. Modeling HCV kinetics during intravenous silibinin monotherapy in the peri-transplant period. J Hepatol 2013; 58:S330-S331.
26. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57:1752-1762.
27. Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58 Suppl S1:86A.
28. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52:951-952.
29. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 2011; 54:591-592.
30. Blaising J, Lévy PL, Gondeau C, et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 2013; 15:1866-1882.
31. Dahari H, Shteingart S, Gafanovich I, et al. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. Liver Int 2015; 35:289-294.